<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00014261</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068523</org_study_id>
    <secondary_id>P30CA023108</secondary_id>
    <secondary_id>DMS-0010</secondary_id>
    <secondary_id>NCI-G01-1924</secondary_id>
    <nct_id>NCT00014261</nct_id>
  </id_info>
  <brief_title>Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase-I Study Of Cyclical Oral Administration Of Temozolomide In Combination With PEG12000-Interferon Alfa-2B In Patients With Refractory And/Or Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. PEG-interferon alfa-2B may interfere with the growth of cancer&#xD;
      cells. Combining temozolomide with PEG-interferon alfa-2B may be an effective treatment for&#xD;
      advanced solid tumors.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining temozolomide and&#xD;
      PEG-interferon alfa-2B in treating patients who have advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and tolerability of temozolomide and PEG-interferon alfa-2b in&#xD;
           patients with advanced refractory solid tumors or chemotherapy-naive advanced cancer.&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) and dose-limiting toxicity of this regimen in&#xD;
           this patient population.&#xD;
&#xD;
        -  Determine the pharmacokinetics of PEG-interferon alfa-2b at the MTD when administered&#xD;
           with temozolomide in this patient population.&#xD;
&#xD;
        -  Determine the anti-tumor activity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive oral temozolomide on days 1-7 and 15-21 and PEG-interferon alfa-2b&#xD;
      subcutaneously on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 1-9 patients receive escalating doses of temozolomide and PEG-interferon alfa-2b&#xD;
      until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose&#xD;
      preceding that at which at least 2 of 3 or 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2000</start_date>
  <completion_date type="Actual">November 2002</completion_date>
  <primary_completion_date type="Actual">November 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEG-interferon alfa-2b</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed advanced solid tumor that is refractory to standard therapy&#xD;
             OR&#xD;
&#xD;
          -  Histologically confirmed chemotherapy-naive advanced cancer for which no curative&#xD;
             therapy or higher priority palliative chemotherapy exists&#xD;
&#xD;
          -  Brain metastasis allowed&#xD;
&#xD;
          -  No bone marrow involvement of tumor&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3 AND/OR&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  ALT or AST less than 3 times upper limit of normal (ULN) (5 times ULN if liver&#xD;
             metastases present)&#xD;
&#xD;
          -  No autoimmune hepatitis&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2.5 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No severe coronary artery disease&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No severe chronic obstructive pulmonary disease&#xD;
&#xD;
        Gastrointestinal:&#xD;
&#xD;
          -  No frequent vomiting&#xD;
&#xD;
          -  No medical condition that would interfere with oral medication intake (e.g., partial&#xD;
             bowel obstruction, partial intestinal bypass, or external biliary diversion)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No known or suspected hypersensitivity to imidazotetrazin, interferon alfa, or any&#xD;
             excipient or vehicle included in the formulation or delivery system of study drug&#xD;
&#xD;
          -  No history of autoimmune disease&#xD;
&#xD;
          -  No preexisting severe psychiatric condition or history of severe psychiatric disorder&#xD;
             (including suicidal ideation or attempt)&#xD;
&#xD;
          -  No life-threatening condition or severe preexisting condition&#xD;
&#xD;
          -  No uncontrolled thyroid abnormalities&#xD;
&#xD;
          -  No nonmalignant systemic disease&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No AIDS-related illness&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 3 weeks since prior biologic agents (e.g., bi-specific antibodies,&#xD;
             interleukin-2, or interferon) and recovered (excluding alopecia)&#xD;
&#xD;
          -  No prior allogeneic, syngeneic, or autologous bone marrow or stem cell transplantation&#xD;
&#xD;
          -  No other concurrent biologic therapy&#xD;
&#xD;
          -  No concurrent colony stimulating factors or epoetin alfa for the prevention of&#xD;
             myelotoxicity&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (more than 6 weeks for nitrosoureas,&#xD;
             melphalan, or mitomycin) and recovered (excluding alopecia)&#xD;
&#xD;
          -  No prior high-dose chemotherapy and stem cell transplantation&#xD;
&#xD;
          -  No more than 3 prior chemotherapy regimens&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 6 weeks since prior wide-field radiotherapy to at least 25% of bone marrow&#xD;
             (e.g., pelvic radiotherapy)&#xD;
&#xD;
          -  More than 6 weeks since prior strontium chloride Sr 89 or samarium Sm 153 lexidronam&#xD;
             pentasodium&#xD;
&#xD;
          -  Recovered from prior radiotherapy (excluding alopecia)&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
&#xD;
          -  At least 1 week since prior minor surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 4 weeks since prior investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lionel D. Lewis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Norris Cotton Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>April 10, 2001</study_first_submitted>
  <study_first_submitted_qc>July 29, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2003</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Lionel.D.Lewis, MD</investigator_full_name>
    <investigator_title>Professor of Medicine and of Pharmacology and Toxicology</investigator_title>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

